Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that on general grounds [1706-1708,2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1706]
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1706]
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
The T Lymphocyte In Experimental Allergic Encephalomyelitis
Zamvil, S. (1990) · Annual Review of Immunology · doi:10.1146/annurev.immunol.8.1.579 · Cited by 1,009
Self-citationMummery, C. J., Patterson, K., Price, C. J., Ashburner, J., Frackowiak, R. S. J., & Hodges, J. R. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<36::aid-ana8>3.0.co;2-l · Cited by 946
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Steinman, L., & Zamvil, S. S. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.014 · Cited by 265
Self-citationExperimental allergic encephalomyelitis: A misleading model of multiple sclerosis
Sriram, S., & Steiner, I. (2005) · Annals of Neurology · doi:10.1002/ana.20743 · Cited by 264
Teitelbaum, D., Webb, C., Meshorer, A., Arnon, R., & Sela, M. (1973) · European Journal of Immunology · doi:10.1002/eji.1830030505 · Cited by 122
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
Giuliani, F., Metz, L. M., Wilson, T., Fan, Y., Bar‐Or, A., & Yong, V. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.09.006 · Cited by 116
Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
Kanwar, J. R., Kanwar, R. K., & Krissansen, G. W. (2004) · Brain · doi:10.1093/brain/awh156 · Cited by 111
Stuve, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25805 · Cited by 107
Self-citationStüve, O., Youssef, S., Slavin, A. J., King, C. L., Patarroyo, J. C., Hirschberg, D. L., Brickey, W. J., Soos, J. M., Piskurich, J. F., Chapman, H. A., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6720 · Cited by 97
Self-citationAn open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS
Calabresi, P. A., Wilterdink, J. L., Rogg, J. M., Mills, P., Webb, A., & Whartenby, K. A. (2002) · Neurology · doi:10.1212/wnl.58.2.314 · Cited by 88
Kerfoot, S. M., Norman, M. U., Lapointe, B. M., Bonder, C. S., Zbytnuik, L., & Kubes, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6225 · Cited by 88
Frohman, E. M., Havrdová, E., LUBLIN, F. D., Barkhof, F., Achiron, A., Sharief, M. K., Stüve, O., Racke, M. K., Steinman, L., Weiner, H. L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.614 · Cited by 85
Self-citationRamtahal, J., Jacob, A., Das, K., & Boggild, M. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0178-z · Cited by 82
Bachmann, R. F., Eugster, H., Frei, K., Fontana, A., & Lassmann, H. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65395-3 · Cited by 78
Effective combination of minocycline and interferon-β in a model of multiple sclerosis
Giuliani, F., Fu, S. A., Metz, L. M., & Yong, V. W. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.020 · Cited by 74
Pharmacologic Principles for Combination Therapy
Toews, M. L., & Bylund, D. B. (2005) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200504-037sr · Cited by 73
Soos, J. M., Stüve, O., Youssef, S., Bravo, M., Johnson, H. M., Weiner, H. L., & Zamvil, S. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2231 · Cited by 63
Self-citationGoldblatt, D. (2001) · Neurology · doi:10.1212/wnl.56.2.148 · Cited by 51
Brod, S. A., Lindsey, J. W., & Wolinsky, J. S. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<127::aid-ana22>3.0.co;2-1 · Cited by 47
EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis
Ransohoff, R. M. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.007 · Cited by 42
Paintlia, A. S., Paintlia, M. K., Singh, I., & Singh, A. K. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051309 · Cited by 37
Combination Therapy for Multiple Sclerosis: The Treatment Strategy of the Future?
Weinstock‐Guttman, B., & Bakshi, R. (2004) · CNS Drugs · doi:10.2165/00023210-200418120-00003 · Cited by 29
Central nervous system infections – a potential complication of systemic immunotherapy
Hemmer, B., Frohman, E., Hartung, H. P., & Stüve, O. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227037.70329.b0 · Cited by 24
Self-citationCombination therapy in multiple sclerosis
Tullman, M. J., & LUBLIN, F. D. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0053-9 · Cited by 19
Martinelli, V. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0692-x · Cited by 16
Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.
Reid, J. L. (1995) · PubMed · Cited by 11
Rationale and experience with combination therapies in multiple sclerosis
Boggild, M. (2006) · Journal of Neurology · doi:10.1007/s00415-006-6008-5 · Cited by 5
The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2
Eugster (1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1521-4141(199807)28:07 · Cited by 2
Research works printed but not linked: 3
- Reid, 1995, J Hum Hypertens, 9, S19
- Zamvil, 1990, Annu Rev Immunol, 8, 579, 10.1146/annurev.iy.08.040190.003051 · doi:10.1146/annurev.iy.08.040190.003051 · Paper page
- Cohen, 2003, Mult Scler, 9, S139
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“and that on general grounds [1706-1708, 2142] such a”
BackgroundIs multiple sclerosis a mitochondrial disease?
Mao, P., & Reddy, P. H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.002 · Cited by 243
“Furthermore, there are good scientific rationales for the use of combination therapy in MS, and the clinical trials are also currently underway to establish the therapeutic efficacy and safety of various combination therapies for MS patients [175] .”
Treatment and management of cognitive dysfunction in patients with multiple sclerosis
DeLuca, J., Chiaravalloti, N. D., & Sandroff, B. M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0355-1 · Cited by 212
Rudick, R. A., & Polman, C. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70082-1 · Cited by 144
Torke, S., Pretzsch, R., Häusler, D., Haselmayer, P., Grenningloh, R., Boschert, U., Brück, W., & Weber, M. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02204-z · Cited by 101
Self-citation
Metadata
- Authors
- Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E.
- Affiliations
- University of Ottawa (CA)
- VA North Texas Health Care System (US)
- University of California, San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Costello, Fiona
- Venue
- Current Opinion in Neurology
- Published
- 2007-06
- Volume
- 20
- Issue
- 3
- Pages
- 281-285
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W1994457578
- Cited by
- 46
- References
- 46
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, combination therapy, experimental autoimmune encephalomyelitis, neurorepair, neuroinflammation, disease activity, investigational drugs, clinical trials
- MeSH terms
- Glatiramer Acetate, Animals, Antibodies, Monoclonal, Clinical Protocols, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Immunologic Factors, Immunotherapy, Multiple Sclerosis, Peptides, Interferon-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.